跳至主要内容
临床试验/NCT02232594
NCT02232594已完成不适用

Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

Boehringer Ingelheim0 个研究点目标入组 834 人开始时间: 2000年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
834
主要终点
Overall severity of the clinical picture rated on a 4- point scale

研究概览

简要总结

The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients of either sex over 40 years with the symptoms of a chronic obstructive airways disease
  • Only patients which have not been treated with Berodual® within the last year should be included

排除标准

  • Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berodual® metered-dose inhaler

研究组 & 干预措施

chronic obstructive respiratory tract disease patients

干预措施: Berodual® (Drug)

结局指标

主要结局

Overall severity of the clinical picture rated on a 4- point scale

时间窗: after 3 and 6 weeks

次要结局

  • Assessment of efficacy by investigator on a 4-point scale(after 3 and 6 weeks)
  • Assessment of tolerability by patient on a 4-point scale(after 3 and 6 weeks)
  • Number of patients with adverse drug reactions(up to 6 weeks)
  • Assessment of efficacy by patient on a 4-point scale(after 3 and 6 weeks)
  • Assessment of tolerability by investigator on a 4-point scale(after 3 and 6 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验